West Pharmaceutical (WST) analyst forecast and price target
Analyst forecast
Consensus of 19 analyst ratings
Based on 7 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Citigroup | Maintained | Buy | $412.00 from $400.00 | Aug 3, 2026 |
| Evercore ISI Group | Maintained | Outperform | $425.00 from $410.00 | Jul 27, 2026 |
| BNP Paribas | Initiated Coverage | Outperform | $447.00 | Jul 13, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $365.00 from $325.00 | Jul 9, 2026 |
| Evercore ISI Group | Maintained | Outperform | $410.00 from $390.00 | Jul 6, 2026 |
| Keybanc | Maintained | Overweight | $390.00 from $350.00 | Jul 2, 2026 |
| Barclays | Upgraded | Equal-Weight → Overweight | $400.00 from $310.00 | Jun 9, 2026 |
| Wolfe Research | Initiated Coverage | Outperform | — | Jun 2, 2026 |
| Stephens & Co. | Maintained | Overweight | $360.00 | Jun 2, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $325.00 from $315.00 | May 29, 2026 |
| Barclays | Maintained | Equal-Weight | $310.00 from $275.00 | Apr 27, 2026 |
| Barclays | Maintained | Equal-Weight | $275.00 from $265.00 | Apr 14, 2026 |
| Barclays | Maintained | Equal-Weight | $265.00 from $325.00 | Feb 13, 2026 |
| Evercore ISI Group | Maintained | Outperform | $320.00 from $390.00 | Feb 3, 2026 |
| Morgan Stanley | Initiated Coverage | Equal-Weight | $285.00 | Dec 2, 2025 |
| TD Cowen | Initiated Coverage | Buy | $350.00 | Oct 29, 2025 |
| Barclays | Maintained | Equal-Weight | $325.00 from $275.00 | Oct 27, 2025 |
| Keybanc | Maintained | Overweight | $350.00 from $325.00 | Oct 24, 2025 |
| UBS | Maintained | Buy | $355.00 from $320.00 | Oct 24, 2025 |
| Evercore ISI Group | Maintained | Outperform | $390.00 from $350.00 | Oct 23, 2025 |
Frequently asked questions
What is the price target for WST stock?
The average 12-month analyst price target for West Pharmaceutical (WST) is $399.86, with a high estimate of $447.00 and a low of $360.00, across 7 analysts.
Is WST a buy, sell, or hold?
Analysts covering West Pharmaceutical currently average a Buy rating: 17 buy, 2 hold and 0 sell, from 19 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for WST?
The average price target of $399.86 implies 17.16% upside from the last price of $341.28.
What is the latest analyst rating on WST?
On Aug 3, 2026, Citigroup maintained West Pharmaceutical at Buy with a price target of $412.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.